Payment overview · 2025
General Payments
$381.14
19 reported records · 13 companies
Healthcare provider profile · identity verified
Paul A Hinton, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LAKE ST LOUIS, MO · NPI 1639130263
Verified facts
What the public records show
CMS Open Payments records show Paul A Hinton, MD received $381.14 in general payments during 2025 across 19 reported records.
Exact Sciences Corporation accounted for 13.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 270 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $51.85 | 13.6% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $48.43 | 12.7% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $44.11 | 11.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $42.28 | 11.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $37.50 | 9.8% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $27.25 | 7.2% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $21.79 | 5.7% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.44 | 5.6% | 1 | 2025 |
| Itamar Medical Inc | Unresolved — no canonical attribution shown | $20.39 | 5.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.70 | 4.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.70 | 4.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.47 | 4.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.23 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $381.14 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $48.43 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $44.11 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $42.28 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $37.50 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.29 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $27.25 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $21.79 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $21.44 | 1 | 2025 |
Source payment records
|
|||||
| WatchPATONE Normalized: watchpatone |
Device | Itamar Medical Inc | $20.39 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $19.56 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 52 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
65 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
50 | 50 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
39 | 32 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
52 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
270 | 46 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 420 | 114 |
| Amlodipine Besylate | Amlodipine Besylate | 361 | 82 |
| Pantoprazole Sodium | Pantoprazole Sodium | 328 | 82 |
| Furosemide | Furosemide | 299 | 69 |
| Levothyroxine Sodium | Levothyroxine Sodium | 294 | 62 |
| Lisinopril | Lisinopril | 289 | 81 |
| Eliquis | Apixaban | 270 | 46 |
| Donepezil Hcl | Donepezil Hcl | 208 | 39 |
| Trazodone Hcl | Trazodone Hcl | 198 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 197 | 48 |
| Metformin Hcl | Metformin Hcl | 196 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 188 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 175 | 40 |
| Gabapentin | Gabapentin | 172 | 53 |
| Losartan Potassium | Losartan Potassium | 171 | 49 |
| Quetiapine Fumarate | Quetiapine Fumarate | 169 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 162 | 38 |
| Omeprazole | Omeprazole | 156 | 33 |
| Sertraline Hcl | Sertraline Hcl | 152 | 30 |
| Famotidine | Famotidine | 147 | 26 |
| Potassium Chloride | Potassium Chloride | 144 | 31 |
| Carvedilol | Carvedilol | 141 | 36 |
| Memantine Hcl | Memantine Hcl | 135 | 22 |
| Tramadol Hcl | Tramadol Hcl | 128 | 50 |
| Mirtazapine | Mirtazapine | 120 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 101 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 99 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 96 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 95 | 19 |
| Warfarin Sodium | Warfarin Sodium | 93 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 89 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 83 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 82 | 31 |
| Pregabalin | Pregabalin | 82 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 79 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 75 | 24 |
| Clonazepam | Clonazepam | 74 | 29 |
| Simvastatin | Simvastatin | 74 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 73 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | 19 |
| Alprazolam | Alprazolam | 68 | 31 |
| Finasteride | Finasteride | 68 | 17 |
| Montelukast Sodium | Montelukast Sodium | 68 | 16 |
| Buspirone Hcl | Buspirone Hcl | 67 | 18 |
| Meloxicam | Meloxicam | 67 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 65 | 33 |
| Farxiga | Dapagliflozin Propanediol | 65 | 13 |
| Lorazepam | Lorazepam | 63 | 18 |
| Levetiracetam | Levetiracetam | 60 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 56 | suppressed |
| Myrbetriq | Mirabegron | 53 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 52 | 35 |
| Jardiance | Empagliflozin | 52 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 52 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 51 | 12 |
| Risperidone | Risperidone | 51 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 50 | 50 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 50 | 27 |
| Januvia | Sitagliptin Phosphate | 49 | suppressed |
| Allopurinol | Allopurinol | 45 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 18 |
| Alendronate Sodium | Alendronate Sodium | 44 | suppressed |
| Glipizide | Glipizide | 44 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 43 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 43 | suppressed |
| Latanoprost | Latanoprost | 42 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 39 | 32 |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Baclofen | Baclofen | 38 | 14 |
| Midodrine Hcl | Midodrine Hcl | 38 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Linzess | Linaclotide | 36 | suppressed |
| Olanzapine | Olanzapine | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | 13 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 33 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 22 |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | suppressed |
| Azithromycin | Azithromycin | 29 | 25 |
| Lansoprazole | Lansoprazole | 29 | suppressed |
| Nystatin | Nystatin | 29 | 18 |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 26 |
| Santyl | Collagenase Clostridium Hist. | 27 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 26 | 12 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 26 | 14 |
| Letrozole | Letrozole | 26 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Digoxin | Digoxin | 25 | suppressed |
| Loperamide | Loperamide Hcl | 25 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Lactulose | Lactulose | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 20 |
| Aripiprazole | Aripiprazole | 22 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Cephalexin | Cephalexin | 22 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Prednisone | Prednisone | 20 | 18 |
| Torsemide | Torsemide | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 11 |
| Fluconazole | Fluconazole | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | 14 |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Lacosamide | Lacosamide | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Azathioprine | Azathioprine | 14 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Atenolol | Atenolol | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Fluorometholone | Fluorometholone | 12 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | 11 |
| Mupirocin | Mupirocin | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $381.14 · 19 records | Exact Sciences Corporation | ABRYSVO, AIRSUPRA, CAPLYTA, COMIRNATY, Cologuard Collection Kit, ENTRESTO, FANAPT, JARDIANCE, JOURNAVX, Kerendia, Korlym, LEQVIO, PREVNAR 20, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, WatchPATONE, Wegovy | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error